New “Old” Therapies in Pulmonary Arterial Hypertension: A Clinical Roundtable
Despite recent strides in elucidating the pathophysiology of pulmonary arterial hypertension (PAH), there have been few advances in the development of novel therapies to treat the disease. The medications currently approved for PAH treatment are most beneficial in the 5% to 10% of patients with PAH who are vasoresponders, although these therapies have been shown… Read More »